Skip to main content
Top
Published in: Digestive Diseases and Sciences 11/2016

01-11-2016 | Correspondence

Response to Feuerstein J et al. “Systematic Analysis and Critical Appraisal of the Quality of the Scientific Evidence and Conflicts of Interest in Practice Guidelines (2005–2013) for Barrett’s Esophagus”. doi:10.1007/s10620-016-4222-2

Authors: Cathy Bennett, Janusz Jankowski, Paul Moayyedi, On behalf of the International BAD CAT and BOB CAT consortia

Published in: Digestive Diseases and Sciences | Issue 11/2016

Login to get access

Excerpt

We read with interest the article by Feuerstein et al. “Systematic analysis and critical appraisal quality of the scientific evidence and conflicts of interest in practice guidelines (2005–2013) for Barrett’s esophagus” [8]. We note the omission of our international consensus guidelines on management of Barrett’s esophagus [1, 2] from this appraisal. While our recent guideline on the management of non-dysplastic and low-grade dysplasia in Barrett’s osophagus “BOB CAT” [2] is outside the date limits of their search for evidence, our 2012 guideline “BAD CAT” [1] should have been retrieved. This guideline was funded and endorsed by numerous international societies, and the resulting publication is highly cited and accredited by NICE (UK) [3]. BAD CAT [1] involved an international panel of 92 authors, and 11,000 articles were assessed on the management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma. Since the management of Barrett’s with dysplasia was not explicitly excluded from the review, it appears that there is no rationale for the exclusion of the BAD CAT guideline. Had our guideline been included, the authors would have noted that we addressed many of the problems and shortcomings identified by their review of other guidelines, using the AGREE II instrument. Specifically, we assessed both the quality of the scientific evidence included in the review using GRADE [4] and reported conflict of interest declarations in detail. The guideline production method was inclusive, with input from all areas of clinical specialty and patient groups; there was consideration of adverse events and harms; it was peer-reviewed prior to publication, and we identified areas which were directly applicable to clinical management. As an evidence-based consensus group, we sought to maintain editorial independence and collected information about conflict of interest. Any participants who did not provide a conflict of interest statement were excluded from authorship, to ensure the impartiality of the process. …
Literature
1.
go back to reference Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology. 2012;143:336–346.CrossRefPubMed Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology. 2012;143:336–346.CrossRefPubMed
2.
go back to reference Bennett C, Moayyedi P, Corley DA, et al. BOB CAT: a large-scale review and Delphi consensus for management of Barrett’s esophagus with no dysplasia, indefinite for, or low-grade dysplasia. Am J Gastroenterol. 2015;110:662–682 (quiz 683).CrossRefPubMedPubMedCentral Bennett C, Moayyedi P, Corley DA, et al. BOB CAT: a large-scale review and Delphi consensus for management of Barrett’s esophagus with no dysplasia, indefinite for, or low-grade dysplasia. Am J Gastroenterol. 2015;110:662–682 (quiz 683).CrossRefPubMedPubMedCentral
4.
go back to reference Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383–394.CrossRefPubMed Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383–394.CrossRefPubMed
5.
go back to reference Das D, Chilton AP, Jankowski JA. Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res. 2009;181:161–169.CrossRefPubMed Das D, Chilton AP, Jankowski JA. Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res. 2009;181:161–169.CrossRefPubMed
6.
go back to reference Old O, Moayyedi P, Love S, et al. Barrett’s oesophagus surveillance versus endoscopy at need study (BOSS): protocol and analysis plan for a multicentre randomized controlled trial. J Med Screen. 2015;22:158–164.CrossRefPubMed Old O, Moayyedi P, Love S, et al. Barrett’s oesophagus surveillance versus endoscopy at need study (BOSS): protocol and analysis plan for a multicentre randomized controlled trial. J Med Screen. 2015;22:158–164.CrossRefPubMed
7.
go back to reference Bennett C, Moayyedi P, Corley DA, et al. Addendum: BOB CAT: a large-scale review and Delphi consensus for management of Barrett’s esophagus with no dysplasia, indefinite for, or low-grade dysplasia. Am J Gastroenterol. 2015;110:943.CrossRefPubMed Bennett C, Moayyedi P, Corley DA, et al. Addendum: BOB CAT: a large-scale review and Delphi consensus for management of Barrett’s esophagus with no dysplasia, indefinite for, or low-grade dysplasia. Am J Gastroenterol. 2015;110:943.CrossRefPubMed
8.
go back to reference Feuerstein JD, Castillo NE, Akbari M, et al. Systematic analysis and critical appraisal of the quality of the scientific evidence and conflicts of interest in practice guidelines (2005–2013) for Barrett’s esophagus. Dig Dis Sci. 2016;61:2812–2822.CrossRefPubMed Feuerstein JD, Castillo NE, Akbari M, et al. Systematic analysis and critical appraisal of the quality of the scientific evidence and conflicts of interest in practice guidelines (2005–2013) for Barrett’s esophagus. Dig Dis Sci. 2016;61:2812–2822.CrossRefPubMed
Metadata
Title
Response to Feuerstein J et al. “Systematic Analysis and Critical Appraisal of the Quality of the Scientific Evidence and Conflicts of Interest in Practice Guidelines (2005–2013) for Barrett’s Esophagus”. doi:10.1007/s10620-016-4222-2
Authors
Cathy Bennett
Janusz Jankowski
Paul Moayyedi
On behalf of the International BAD CAT and BOB CAT consortia
Publication date
01-11-2016
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 11/2016
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-016-4279-y

Other articles of this Issue 11/2016

Digestive Diseases and Sciences 11/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.